Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

IBB vs. RYOIX: which is better?

Bottom line

IBB vs RYOIX: the short answer

IBB (iShares Biotechnology ETF) and RYOIX (Biotechnology Fund) share a meaningful slice of their top holdings — about 55% by weight.

But IBB is far broader, holding 254 positions to 74 for RYOIX, so beyond the top names it adds exposure RYOIX doesn't have.

IBB is cheaper at 0.44% vs 1.38% — a difference of $94 a year per $10,000 invested.

Over five years, RYOIX returned +4.0% a year vs +2.5% for IBB.

Updated Nov 19, 2026

IBB vs RYOIX side by side

IBBRYOIX
TypeETFMutual fund
Fund familyiSharesGuggenheim
CategoryTechnology SectorTechnology Sector
Expense ratio0.44%1.38%
Annual cost per $10k$44$138
10-yr cost on $10k (prospectus)$555$1,709
Max front loadNone—
12b-1 fee0%0%
1-yr return+28.0%+30.7%
5-yr return (annualized)+2.5%+4.0%
10-yr return (annualized)+4.4%+5.9%
Best quarter+26.8%+28.3%
Worst quarter−22.9%−22.5%
Net assets (fund)$5.9B$136.8M
Number of holdings25474
Portfolio turnover27%75%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearIBBRYOIXDifference
2025+28.0%+30.7%−2.7%
2024−2.4%−0.7%−1.7%
2023+3.6%+6.1%−2.4%
2022−13.6%−13.1%−0.5%
2021+1.0%+1.8%−0.8%
2020+25.9%+22.1%+3.8%
2019+24.8%+25.0%−0.3%
2018−9.1%−9.0%−0.2%
2017+21.2%+29.7%−8.5%
2016−21.5%−19.5%−2.0%

Source: Fund prospectus bar charts

Holdings overlap

16 of IBB's top 25 holdings also appear in RYOIX's top 25.

Shared top holdings
HoldingIBBRYOIX
Vertex Pharmaceuticals, Inc.7.66%4.32%
Gilead Sciences, Inc.7.52%4.49%
Amgen, Inc.7.50%5.05%
Regeneron Pharmaceuticals, Inc.5.70%2.93%
Alnylam Pharmaceuticals, Inc.5.68%2.36%
Argenx SE3.15%1.48%
Insmed, Inc.2.95%1.79%
Natera, Inc.2.11%2.12%
BeOne Medicines Ltd.2.11%2.17%
Biogen, Inc.2.03%2.13%
United Therapeutics Corp.1.82%1.72%
Incyte Corp.1.62%1.62%
Illumina, Inc.1.41%1.94%
Neurocrine Biosciences, Inc.1.34%1.52%
Ionis Pharmaceuticals, Inc.1.03%1.35%

Source: SEC Form N-PORT

IBB top 10

  1. BlackRock Funds III — 13.18%
  2. Vertex Pharmaceuticals, Inc. — 7.66%
  3. Gilead Sciences, Inc. — 7.52%
  4. Amgen, Inc. — 7.50%
  5. Regeneron Pharmaceuticals, Inc. — 5.70%
  6. Alnylam Pharmaceuticals, Inc. — 5.68%
  7. IQVIA Holdings, Inc. — 3.18%
  8. Argenx SE — 3.15%
  9. Insmed, Inc. — 2.95%
  10. Mettler-Toledo International, Inc. — 2.49%

RYOIX top 10

  1. Abbvie Inc — 8.17%
  2. Amgen Inc — 5.05%
  3. Gilead Sciences Inc — 4.49%
  4. Vertex Pharmaceuticals Inc — 4.32%
  5. Regeneron Pharmaceuticals Inc — 2.93%
  6. Revolution Medicines Inc — 2.48%
  7. Alnylam Pharmaceuticals Inc — 2.36%
  8. Beone Medicines Ltd — 2.17%
  9. Moderna Inc — 2.15%
  10. Biogen Inc — 2.13%

FAQ

What is the difference between IBB and RYOIX?
IBB (iShares Biotechnology ETF) and RYOIX (Biotechnology Fund) share a meaningful slice of their top holdings — about 55% by weight. But IBB is far broader, holding 254 positions to 74 for RYOIX, so beyond the top names it adds exposure RYOIX doesn't have.
Which is cheaper, IBB or RYOIX?
IBB has the lower expense ratio (0.44%).
Should I own both IBB and RYOIX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.